These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17517836)

  • 41. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
    Adams DA; Riggs MM; Donskey CJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2674-8. PubMed ID: 17562807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
    Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
    J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular epidemiology and antimicrobial susceptibility of human Clostridium difficile isolates from a single institution in Northern China.
    Wang B; Lv Z; Zhang P; Su J
    Medicine (Baltimore); 2018 Jun; 97(25):e11219. PubMed ID: 29924052
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro.
    Spigaglia P; Barbanti F; Louie T; Barbut F; Mastrantonio P
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2463-8. PubMed ID: 19364867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile.
    Drudy D; Quinn T; O'Mahony R; Kyne L; O'Gaora P; Fanning S
    J Antimicrob Chemother; 2006 Dec; 58(6):1264-7. PubMed ID: 17018563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
    Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR
    J Antimicrob Chemother; 2021 Jun; 76(7):1815-1821. PubMed ID: 33895826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
    Kouhsari E; Douraghi M; Krutova M; Fakhre Yaseri H; Talebi M; Baseri Z; Moqarabzadeh V; Sholeh M; Amirmozafari N
    J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.
    Sholeh M; Krutova M; Forouzesh M; Mironov S; Sadeghifard N; Molaeipour L; Maleki A; Kouhsari E
    Antimicrob Resist Infect Control; 2020 Sep; 9(1):158. PubMed ID: 32977835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surveillance of antimicrobial susceptibilities reveals high proportions of multidrug resistance in toxigenic Clostridium difficile strains in different areas of Poland.
    Lachowicz D; Pituch H; Wultańska D; Kuijper E; Obuch-Woszczatyński P
    Anaerobe; 2020 Apr; 62():102167. PubMed ID: 32109736
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
    Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
    Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland.
    Mutlu E; Wroe AJ; Sanchez-Hurtado K; Brazier JS; Poxton IR
    J Med Microbiol; 2007 Jul; 56(Pt 7):921-929. PubMed ID: 17577057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
    Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
    Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence, genetic characteristics, and antimicrobial resistance of Clostridioides difficile isolates from horses in Korea.
    Lee YR; Lee K; Byun JW; Kim H; So B; Ku BK; Kim HY; Moon BY
    Anaerobe; 2023 Apr; 80():102700. PubMed ID: 36716814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
    Miller MA; Blanchette R; Spigaglia P; Barbanti F; Mastrantonio P
    J Clin Microbiol; 2011 Dec; 49(12):4319-21. PubMed ID: 21998414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
    Cheng JW; Liu C; Kudinha T; Xiao M; Fan X; Yang CX; Wei M; Liang GW; Shao DH; Xiong ZJ; Hou X; Yu SY; Wang Y; Yang QW; Su JR; Xu YC
    Int J Antimicrob Agents; 2020 Jul; 56(1):105981. PubMed ID: 32330584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular characterization of toxigenic Clostridium difficile in a northern Italian hospital.
    De Rosa FG; Cavallerio P; Corcione S; Parlato C; Fossati L; Serra R; Di Perri G; Cavallo R
    Curr Microbiol; 2015 Feb; 70(2):154-5. PubMed ID: 25245958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Susceptibility of hamsters to Clostridium difficile isolates of differing toxinotype.
    Buckley AM; Spencer J; Maclellan LM; Candlish D; Irvine JJ; Douce GR
    PLoS One; 2013; 8(5):e64121. PubMed ID: 23704976
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population.
    Mezoff E; Mann EA; Hart KW; Lindsell CJ; Cohen MB
    J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):437-41. PubMed ID: 21407116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.
    Kociolek LK; Gerding DN; Osmolski JR; Patel SJ; Snydman DR; McDermott LA; Hecht DW
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4896-900. PubMed ID: 27270275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.